The Escherichia Coli Strain Market is estimated to be
valued at US$ 1.97 Bn or Mn in 2023 and is expected to exhibit a CAGR of 6.9%
over the forecast period 2023 to 2030, as highlighted in a new report published
by Coherent Market Insights.
Market Overview:
Escherichia coli (E. coli) is a gram-negative, facultative anaerobic,
rod-shaped bacterium commonly found in the lower intestine of warm-blooded
organisms. E. coli strains are widely used in biotechnology as they are easy to
grow and manipulate. Various E. coli strains are used for the production of
therapeutic proteins including insulin, growth factors, and monoclonal
antibodies. They are also used in molecular biology techniques such as cloning
and protein expression.
Market Dynamics:
One of the key drivers for the E. coli strain market is increasing demand for
biopharmaceuticals. Recombinant therapeutic proteins developed using E. coli
strains are gaining acceptance over conventional drugs due to advantages such
as high specificity, low toxicity, and easy availability. Furthermore,
advancements in genome engineering technologies such as CRISPR/Cas9 have
simplified the manipulation and optimization of E. coli genomes. This has
facilitated the development of novel E. coli strains with enhanced protein
production capabilities, inclusion body formation, and reduced endotoxin
levels.
Additionally, rising investments by biotech and pharmaceutical companies in
cell line development also supports the market growth. Modifying E. coli
strains to produce complex biologics safely and efficiently can help reduce
production costs considerably. This is inducing greater R&D towards
engineering novel E. coli with human-compatible glycosylation abilities.
Segment
Analysis
The global Escherichia Coli Strain Market is segmented into sub-types namely,
cloning strains, expression strains and high-copy strains. Among these, the
expression strains segment dominates the market with around 40% share owing to
their widespread applications in protein expression using vector cloning. Expression
strains offer advantages such as high protein yield, no deletions or mutations
in genes and post-translational modifications.
PEST Analysis
Political: The market is positively impacted by government initiatives and
funding for research in life sciences, personalized medicine and genetic
engineering.
Economic: The recent economic growth in emerging nations has boosted
investments in healthcare and biotechnology research thereby driving market
growth.
Social: Rising awareness about personalized medicine, genetic disorders and
disease diagnostics has increased the adoption of E. coli strains in research
activities.
Technological: Advancements in gene cloning, genetic engineering and
recombinant DNA technology have enabled development of improved E. coli strains
with enhanced protein expression capabilities and safety profile.
Key Takeaways
Global
Escherichia Coli Strain Market Demand is expected to witness high
growth, exhibiting CAGR of 6.9% over
the forecast period, due to increasing investments by pharmaceutical and
biotechnology companies in protein production and development of therapeutics
using recombinant DNA technology.
The North America region dominates the market with over 30% share owing to
presence of leading life science research institutes and companies in the US
and Canada. Asia Pacific is expected to witness fastest growth during the
forecast period supported by rising biotechnology research activities in China,
India and Japan.
Key players operating in the Escherichia Coli Strain Market are Thermo Fisher
Scientific Inc., Merck KGaA, Novozymes A/S, QIAGEN N.V., Promega Corporation,
Agilent Technologies, Inc., New England Biolabs, Inc., Takara Bio Inc., Bio-Rad
Laboratories, Inc., GenScript Biotech Corporation. These players are focusing
on new product launches, partnerships and expansions to increase their market
share.
Comments
Post a Comment